Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 70

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 70
---
 of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive twelve-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. As of December 31, 2024, the 2024 Milestone was not met and the possible outcomes for the remaining 2025 Milestone contingent consideration is $0 or $25.0 million on an undiscounted basis. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated revenue projections, volatility, estimated discount rates and risk-free interest rate.

113

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)6. Contingent Consideration (Continued)

Change in the Fair Value of Contingent ConsiderationThe following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):USWM AcquisitionAdamas AcquisitionTotalBalance, December 31, 2021$70,170 $10,307 $80,477 Milestone payments(25,000)— (25,000)Change in fair value recognized in earnings1,100 (1,610)(510)Balance, December 31, 202246,270 8,697 54,967 Change in fair value recognized in earnings130 (1,647)(1,517)Balance, December 31, 202346,400 7,050 53,450 Change in fair value recognized in earnings940 (7,050)(6,110)Balance, December 31, 2024$47,340 $— $47,340 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•For the year ended December 31, 2024, the Company recorded a $0.9 million expense which was primarily driven by passage of time, as well as the change in timing of milestone achievement and estimated discount rate.•For the year ended December 31, 2023, the Company recorded a $0.1 million expense which was primarily driven by the passage of time and, as well as the change in timing of milestone achievement and estimated discount rate. •For the year ended December 31,